A phase 2 prospective trial of cabozantinib as first-line treatment for metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2) clinical trial information—NCT03354884.

Giuseppe Procopio,Pierangela Sepe,Sebastiano Buti,Melanie Claps,Maurizio Colecchia,Loris De Cecco,Devecchi Andrea,Matteo Dugo,Chiara Gargiuli,Patrizia Giannatempo,Valentina Guadalupi,Luigi Mariani,Arianna Ottini,Marialuisa Sensi,Filippo de Braud,Elena Verzoni

A phase 2 prospective trial of cabozantinib as first-line treatment for metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2) clinical trial information—NCT03354884.

2021

Giuseppe Procopio
Pierangela Sepe
Sebastiano Buti
Melanie Claps
Maurizio Colecchia
Loris De Cecco
Devecchi Andrea
Matteo Dugo
Chiara Gargiuli
Patrizia Giannatempo
Valentina Guadalupi
Luigi Mariani
Arianna Ottini
Marialuisa Sensi
Filippo de Braud
Elena Verzoni

4571Background: Metastatic collecting ducts carcinoma (mCDC) is a rare disease with bad prognosis and no standard treatments. Due to its rarity, mCDC is biologically poorly characterized and under-...

Keywords:

Internal medicine
Medicine
Carcinoma
Oncology
Renal cell carcinoma
Cabozantinib
Rare disease
Clinical trial
prospective trial
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations